Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:acquiredBy |
gptkb:Luminex_Corporation
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:CEO |
gptkb:Carlo_Rosa
|
| gptkbp:country |
gptkb:Italy
|
| gptkbp:founded |
1968
|
| gptkbp:founder |
gptkb:Carlo_Rosa
|
| gptkbp:headquarters_location |
gptkb:Saluggia,_Italy
|
| https://www.w3.org/2000/01/rdf-schema#label |
DiaSorin S.p.A.
|
| gptkbp:industry |
gptkb:biotechnology
diagnostics |
| gptkbp:listed_in_index |
gptkb:FTSE_Italia_Mid_Cap
|
| gptkbp:mainActivity |
development, production, and marketing of diagnostic tests
|
| gptkbp:market |
global
|
| gptkbp:numberOfEmployees |
over 2,000
|
| gptkbp:products |
molecular diagnostics
immunodiagnostics |
| gptkbp:revenue |
over €1 billion (2022)
|
| gptkbp:stockExchange |
Borsa Italiana
|
| gptkbp:stockSymbol |
gptkb:DIA
|
| gptkbp:website |
https://www.diasorin.com/
|
| gptkbp:bfsParent |
gptkb:DiaSorin
gptkb:LMNX |
| gptkbp:bfsLayer |
7
|